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Many mucosal pathogens, including Neisseria gonorrhoeae, produce proteases that cleave immunoglobulin A
(IgA), the predominant immunoglobulin class produced at mucosal surfaces. While considerable circumstan-
tial evidence suggests that IgA1 protease contributes to gonococcal virulence, there is no direct evidence that
N. gonorrhoeae requires IgA1 protease activity to infect a human host. We constructed a N. gonorrhoeae iga
mutant without introducing new antibiotic resistance markers into the final mutant strain and used human
experimental infection to test the ability of the mutant to colonize the male urethra and to cause gonococcal
urethritis. Four of the five male volunteers inoculated with the Iga2 mutant became infected. In every
respect—clinical signs and symptoms, incubation period between inoculation and infection, and the proportion
of volunteers infected—the outcome of human experimental infection with FA1090iga was indistinguishable
from that previously reported for a variant of parent strain FA1090 matching the mutant in expression of Opa
proteins, lipooligosaccharide, and pilin. These results indicate that N. gonorrhoeae does not require IgA1
protease production to cause experimental urethritis in males.
Immunoglobulin A (IgA) is the predominant Ig produced at
mucosal surfaces. While the extent of its contribution to host
defenses is unclear, IgA appears to perform a number of po-
tentially beneficial functions, including inhibition of bacterial
adherence (3). Many pathogens that colonize mucosal surfaces
produce IgA1 proteases, proteins that cleave within the heavy
(a)-chain hinge of the IgA isotype IgA1 to produce intact Fab
and Fc fragments (reviewed in references 25 and 26). IgA1
proteases are generally made by pathogenic members of the
genera Neisseria and Haemophilus but not by nonpathogenic
members. The mucosal secretions of patients colonized with
certain IgA1 protease-producing bacteria possess IgA1 pro-
tease activity and/or contain IgA1 fragments, and it has often
been theorized that IgA1 protease may facilitate colonization
by cleaving secretory IgA1 (2, 16).
Almost all known strains of Neisseria gonorrhoeae, the caus-
ative agent of the sexually transmitted disease gonorrhea, pro-
duce IgA1 protease (18, 24, 27, 28). Each strain produces one
of two similar types of the enzyme (type 1 or type 2), which
cleave different bonds (Pro-Ser and Pro-Thr, respectively) in
the 18-amino-acid hinge region of human IgA1. Production of
gonococcal IgA1 protease involves self-directed secretion and
autocatalytic processing of a larger precursor protein encoded
by the iga gene (reviewed in reference 17). Processing leads to
release of the mature protease plus two smaller fragments, the
a and g peptides. Recently, alternative roles in gonococcal
pathogenesis other than cleavage of IgA1 at mucosal surfaces
have been proposed for IgA1 protease and for the a peptide.
IgA1 protease cleaves synaptobrevin II in vitro and, when
introduced into the cytosol of bovine chromaffin cells, blocks
exocytosis (1). The type 2 IgA1 protease cleaves LAMP1 (ly-
sosome/late endosome-associated membrane protein 1), and
intracellular N. gonorrhoeae localizes to LAMP1-positive com-
partments in both epithelial cells and phagocytes (10). Lin et
al. (20) also demonstrated cleavage of LAMP1 by neisserial
type 2 IgA1 protease and found that LAMP1 was degraded at
a higher rate in an epithelial cell line infected with wild-type N.
gonorrhoeae than in uninfected cells or in cells infected with an
iga mutant. The iga mutant grew poorly relative to the wild-
type strain in these epithelial cells (20). Pohlner et al. (29)
recently showed that the a peptide targets eukaryotic nuclei
and proposed that it may influence host cell gene expression.
These findings suggest that IgA1 protease and other iga gene
products may contribute to neisserial pathogenesis at intracel-
lular stages of the infection process. However, a gonococcal iga
mutant was not impaired in its ability to invade human fallo-
pian tube organ cultures (5).
The role played by IgA1 protease in infecting a host with an
intact immune system has never been addressed. For N. gon-
orrhoeae, infection occurs only in humans, and no convenient
animal models of mucosal infection are available. However,
human challenge studies can be used to assess the role of
specific virulence factors in gonococcal pathogenesis. A human
model of infection is particularly well suited for assessment of
gonococcal IgA1 protease function, because neisserial IgA1
proteases cleave only the IgA of humans and closely related
primates (reviewed in reference 21). Experimental infection of
male volunteers with N. gonorrhoeae is safe and successfully
reproduces the signs and symptoms of natural infection (4, 14,
23, 32, 35, 36). In this study, we tested the ability of an N.
gonorrhoeae FA1090 iga mutant (designated FA1090iga) to
infect male subjects in the human challenge model of urethral
infection.
MATERIALS AND METHODS
Bacterial strains and growth conditions. N. gonorrhoeae FA1090 was originally
a cervical isolate from a patient with disseminated gonococcal infection; it is
streptomycin resistant (Smr) and is sensitive to both ceftriaxone and ciprofloxa-
cin. FA1090 variants A21 and A22 have been characterized and used previously
in human experimental infections (4, 12, 33). The A22 stock was created by a
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single passage of the original A21 variant and was given a new designation; the
two variants are identical in all tested phenotypes (4, 9, 12). Gonococci were
grown as previously described (4). For IgA1 protease activity assays, gonococci
were grown in gonococcal base (GCB) broth plus Kellogg’s supplements and 5
mM sodium bicarbonate at 37°C with shaking (14). Where appropriate, the
medium was supplemented with erythromycin (5 mg/ml) or streptomycin (10.5
mg/ml). Escherichia coli DH5aMCR (Life Technologies, Gaithersburg, Md.) and
SURE (Stratagene, La Jolla, Calif.) were grown at 37°C in Luria-Bertani broth
or on Luria-Bertani agar supplemented with 100 mg of ampicillin per ml and 250
mg of erythromycin per ml where appropriate. For blue/white b-galactosidase
activity detection, the plates were spread with 40 ml of 5-bromo-4-chloro-3-
indolyl-b-D-galactopyranoside (X-Gal) (20 mg/ml) and 4 ml of isopropyl-b-D-
thiogalactopyranoside (IPTG) (200 mg/ml) before the bacteria were plated.
Recombinant DNA techniques and PCR. Restriction enzymes, DNA-modify-
ing enzymes, and buffers were obtained from New England Biolabs (Beverly,
Mass.) and Life Technologies. PCR reagents were obtained from Boehringer
Mannheim (Indianapolis, Ind.), and Life Technologies. Oligonucleotides were
synthesized by the University of North Carolina Nucleic Acids Core Facility or by
Life Technologies. Unless otherwise noted, PCR mixtures contained 50 pmol of
each primer, 250 mM each deoxynucleoside triphosphate, 2.5 to 5.0 U of Taq
polymerase, and manufacturer’s recommended buffer plus MgCl2. DNA was
sequenced at the University of North Carolina at Chapel Hill. Automated DNA
Sequencing Facility on a model 373A DNA Sequencer (Applied Biosystems,
Foster City, Calif.) with the Taq DyeDeoxy Terminator cycle-sequencing kit
(Applied Biosystems). Probes for colony blots were prepared by enhanced
chemiluminescence direct-labeling or 39-oligolabeling methods (Amersham, Ar-
lington Heights, Ill.). When 39-oligolabeling was used, the hybridization temper-
atures ranged from 13 to 17°C below the oligonucleotide melting temperature.
Southern blots were performed by standard methods with hybridization temper-
atures 11°C below the oligonucleotide melting temperature (31).
Construction of the N. gonorrhoeae FA1090 iga mutant. We constructed a
derivative of the vector pUC19 containing the gonococcal uptake sequence that
is required for transformation of N. gonorrhoeae (7). Complementary oligonu-
cleotides Upt1 (59-GGGCAAGCTTGCCGTCTGAAAAGCTTGGGC-39) and
Upt2 (59-GCCCAAGCTTTTCAGACGGCAAGCTTGCCC-39) (100 pmol
each) were boiled for 5 min and then annealed by slow cooling to room tem-
perature. The annealed oligonucleotides, containing one copy of the gonococcal
uptake sequence flanked by HindIII sites (underlined), were digested with
HindIII and cloned into the HindIII site of plasmid pUC19 to create plasmid
pUPT1.
A 1,350-bp fragment of the N. gonorrhoeae FA1090 iga gene was amplified by
PCR with primers Iga1 and Iga2, which were derived from the sequence of the
iga gene of strain MS11 (28). The amplified fragment was part of the segment of
the iga gene encoding the mature IgA1 protease product (Fig. 1). Primers Iga1
and Iga2 corresponded to regions that are conserved in neisserial iga genes from
different strains (8, 22, 28). Iga1 (59-GGGAATTCGATAACGCCGGCACCGT
CAAAGG-39; nucleotides 1082 to 1104 of MS11 iga) introduced an EcoRI site
(underlined), and Iga2 (59-CCGGATCCCCGGTATAGTCCGAGCGCACGC-
39; nucleotides 2451 to 2430) introduced a BamHI site (underlined). N. gonor-
rhoeae FA1090 chromosomal DNA served as template. The PCR consisted of 30
cycles of 2 min at 96°C, 2 min at 55°C, and 3.5 min at 72°C. Following BamHI and
EcoRI digestion of the PCR product and of pUPT1, the Iga1-Iga2 PCR product
was cloned into the pUPT1 multiple-cloning site, creating plasmid pUI. The
partial sequence (.450 bp) of the pUI insert confirmed the identity of the cloned
fragment. After we cloned the iga fragment, the sequence of the FA1090 iga gene
became available from the gonococcal genome-sequencing project; the sequence
of the clone was 99% identical to the preliminary sequence from the FA1090
genome project (30).
Primers ER1 and ER2 were used to amplify the 2.3-kb ermC9-rpsL cassette
from plasmid pFLOB4250 (13). The PCR conditions were the same as those
described for amplification of iga. ER1 (59-GCGGCAGATCTTGCCCGTTAC
AGAAAGTGG-39) and ER2 (59-GGCTCTGAGATCTTAAACGGTTGACAA
GCCG-39) introduced BglII sites (underlined) flanking the ermC9-rpsL cassette
in the resultant PCR product. The ER1-ER2 PCR product was digested with
BglII and cloned into the unique BglII site within the iga gene in pUI, resulting
in plasmid pUIE.
Complementary oligonucleotides IL1 (59-GGAGATCTAGTTAATTAACGT
CAGATCTGG-39) and IL2 (59-CCAGATCTGACGTTAATTAACTAGATCT
CC-39) (100 pmol each) were annealed and purified as described above. The
annealed oligonucleotides, containing a central PacI site (doubly underlined)
flanked by BglII sites (underlined), were cloned into the BglII site within the iga
gene in plasmid pUI. The resulting plasmid, containing the IL1-IL2 linker (des-
ignated IgaStop) within the iga gene, was designated pUIL. IgaStop created a
frameshift and encoded translational stops in all three frames.
Gonococcal transformations were performed by a plate-spot transformation
method. Piliated gonococci were streaked on GCB agar, and approximately 1 mg
of DNA in 13 SSC (0.15 M NaCl, 0.015 sodium citrate) was spotted on the
freshly streaked bacteria. After overnight incubation, colonies from the areas in
which DNA was spotted were streaked onto selective media and incubated
overnight; the resulting colonies were single-colony purified and rescreened for
appropriate antibiotic resistance and sensitivity. Plasmid pUIE was transformed
into N. gonorrhoeae FA1090 A22, selecting for erythromycin resistance and
screening for streptomycin sensitivity. An erythromycin-resistant, streptomycin-
sensitive transformant was transformed with plasmid pUIL, selecting for strep-
tomycin resistance and screening for erythromycin sensitivity. A transformant
that was Iga2 by both Southern blot analysis and IgA1 protease activity assay was
designated FA1090iga.
IgA1 protease activity assay. IgA1 protease activity assays were performed as
described by St. Geme et al. (34) with minor modifications. Gonococci were
grown in GCB broth to a turbidity of 150 Klett units as measured with a
Klett-Summerson colorimeter (approximately 4 3 108 CFU per ml). Aliquots of
the cultures were centrifuged for 2 min at 15,000 3 g in a microcentrifuge.
Culture supernatant (10 ml) was added to 5 ml of human IgA1 (0.5 mg/ml;
Calbiochem, La Jolla, Calif.), and chloramphenicol was added to a final concen-
tration of 2 mg/ml. Samples were incubated overnight at 37°C, subjected to
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) on a
12% polyacrylamide gel with Laemmli buffers, and transferred to 0.45-mm-pore-
size Optitran supported nitrocellulose (Schleicher & Schuell, Keene, N.H.) (19).
The filters were probed with anti-human IgA (a-chain specific)-peroxidase con-
jugate (1:5,000) (Sigma, St. Louis, Mo.) followed by the enhanced chemilumi-
nescence substrate (Amersham, Arlington Heights, Ill.).
Preparation of FA1090iga inoculum. We isolated a variant of strain FA1090iga
that was matched in expression of variable surface components to FA1090 A21
and A22, the variants we have used in the majority of the human challenge
experiments with this strain. FA1090 A21 and A22 are Opa negative and piliated
and express three lipooligosaccharide (LOS) species, including one that binds
monoclonal antibody (MAb) 3F11. Pilin expressed by these variants is derived
entirely from the pilS6c1 storage copy; the variants produce full-length pilin plus
some S-pilin (reference 9 and data not shown). The LOS phenotype was char-
acterized by SDS-PAGE of proteinase K-treated lysates as previously described
(12). Expression of Opa proteins was assessed by colony immunoblotting with
MAbs specific for the Opa proteins of strain FA1090 and by observation of the
colony opacity phenotype under a dissecting microscope, as previously described
(12). Piliation was assessed by (i) determination of colony morphology, (ii)
Western blot analysis of pilin expression with a polyclonal anti-pilin antiserum,
(iii) competence for genetic transformation by a quantitative assay measuring the
transformation frequency for the chromosomal rifampin resistance marker, and
(iv) determination of the DNA sequence of the pilE expression locus. The pilE
locus was amplified with primers pilstart (59-GAGATAAACGCATAAAATTT
CACC-39) and sp3a (59-CCGGAACGGACGACCCCG-39), using FA1090iga
freezer stock diluted in water and boiled as the template (33). The PCR product
was sequenced directly with sequencing primer pilAW (59-CCTACCAAGACT
ACACCGCCC-39).
After isolation of an appropriate variant, designated FA1090iga 15b, the vari-
ant was expanded and a suspension of cells was divided into multiple aliquots,
which were stored at 270°C in freezer storage medium (FSM) (12). One vial of
this group was thawed and cultured, and all of the above phenotypes were
reconfirmed. In addition, we determined that (i) the mutant strain grew on GCB
agar containing VCN selective supplement (Oxoid, Basingstoke, United King-
dom) (used for culture of specimens from experimentally infected subjects), (ii)
the mutant strain survived in urine as well as the wild-type parent did (a property
that might affect the recovery of viable organisms from urine specimens), and
(iii) the relationship between the turbidity of a suspension measured with a
Klett-Summerson colorimeter and CFU per milliliter was the same as that for
the parent strain (the inoculation procedure involves suspending the organisms
in phosphate-buffered saline to a Klett reading that was previously determined to
correspond to the desired number of CFU). The sensitivity of the mutant strain
to ceftriaxone and ciprofloxacin was confirmed by the Clinical Microbiology
Laboratory of University of North Carolina Hospitals.
Two days prior to inoculation, FA1090iga 15b was streaked onto GCB agar,
using a freezer stock that had never been thawed. The following day (approxi-
mately 20 h before inoculation of volunteers), colonies were observed under a
dissecting microscope. Two separate suspensions of colonies were made by
FIG. 1. Illustration of the gonococcal iga gene, based on the sequence pub-
lished by Pohlner et al. (28). The portion of the iga gene encoding the mature
IgA1 protease is unshaded. Primers Iga1 and Iga2 were used in PCR to amplify
the iga gene fragment for cloning. The BglII site shown was used subsequently for
insertional inactivation of the gene, as described in the text. Shaded areas encode
portions of the protein that are not part of the mature protease. The signal
peptide (SP) and b domain (b) remain in the inner and outer membranes,
respectively, during export, and the a peptide (a) and g peptide (g) are cleaved
off following export to produce the mature IgA1 protease. This export model is
reviewed by Klauser et al. (17).
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picking approximately 30 colonies with appropriate transparent, piliated mor-
phology into a small amount of GCB broth. These suspensions were streaked
onto fresh GCB agar plates. The Opa-negative phenotype of the two suspensions
was confirmed by immunoblotting with anti-FA1090 Opa MAbs. On the day of
the trial, the colonies cultured from the two suspensions were examined under a
dissecting microscope to confirm that the colonies were predominantly (.90%)
piliated and transparent. The inoculum was prepared with some colonies derived
from each of the two suspensions. The bacterial inoculum was suspended in
phosphate-buffered saline, passed through a 1.2-mm-pore-size filter, and quan-
titated as previously described (4, 12).
Experimental infection of human subjects. Male subjects were recruited and
screened as previously described (4), and procedures for experimental infection
of subjects were as previously described (4). The subjects gave informed consent
and were compensated for their participation. They were examined by a physi-
cian at least twice daily for signs and symptoms of infection, and urethral swab
specimens were collected, Gram stained, and cultured as soon as a subject
developed a urethral exudate. Urine specimens from all subjects were cultured
quantitatively each morning, and the total number of CFU washed from the
urethra in each urine specimen was calculated. The volumes of the urine spec-
imens and thus the concentrations of organisms in those specimens were widely
variable; the culture results were therefore expressed as total CFU/urine speci-
men. The subjects were treated with ceftriaxone or ciprofloxacin immediately
upon the appearance of signs or symptoms of infection. Subjects who did not
become infected were treated at the end of the 5-day trial. Urethral swab
specimens and colonies cultured from infected subjects were stored in FSM at
270°C. The protocols were reviewed and approved by the Institutional Review
Board, the Institutional Biosafety Committee, and the General Clinical Research
Center Advisory Board of the University of North Carolina at Chapel Hill.
Genotypic analysis of trial reisolates. Colonies cultured from experimentally
infected subjects were picked individually from primary isolation plates into 25 ml
of FSM in microtiter wells and stored at 270°C. To confirm the inactivation of
the iga gene, a portion of the gene was amplified by PCR with oligonucleotides
Iga1 and Iga2 as described above, using Platinum Taq polymerase (Life Tech-
nologies). For the template in the PCRs, 2 ml of the FSM stock of one colony was
added to the complete PCR mixture, which was incubated for 10 min at 94°C
before the cycling program was started. The resulting PCR products were di-
gested with PacI and analyzed by gel electrophoresis.
RESULTS
Construction of an Iga2 mutant of N. gonorrhoeae FA1090.
To study the role played by gonococcal IgA1 protease in the
early stages of urethral infection, we constructed an Iga2 mu-
tant of strain FA1090 (FA1090iga) for use in experimental
human infection. The FA1090 genome (30) contains a single
iga gene with features characteristic of one encoding a type 2
IgA1 protease (28). To minimize any potential risk to trial
subjects, we used a two-step transformation procedure for con-
structing gonococcal mutants containing no new antibiotic re-
sistance markers (13). Strain FA1090 is Smr and erythromycin
sensitive (Erms). In the first step of the strain construction
(described in detail in Materials and Methods), the FA1090
chromosomal iga gene was insertionally inactivated by intro-
ducing an ermC9-rpsL cassette into it by allelic exchange.
Transformants were selected by the ermC9-encoded Ermr. The
introduction of rpsL, which encodes E. coli ribosomal protein
S12, conferred Sms on the transformants, due to the domi-
nance of Sms over Smr in an Sms/Smr merodiploid. In the
second step, the ermC9-rpsL cassette in one of the Ermr Sms
first-step transformants was replaced by allelic exchange with
an iga allele containing the IgaStop linker, which insertionally
inactivated the gene by both changing its reading frame and
introducing translational termination codons in all three
frames. Transformants were selected for Smr and screened for
Erms. The second step thus restored the Smr Erms phenotype
of the parent strain. One of the Smr Erms transformants
(shown below to have the correct genotype and IgA1 protease
phenotype) was designated FA1090iga. We isolated a variant
of FA1090iga (variant 15b) that was identical to the parent
(FA1090 variant A22) with regard to variable attributes that
might influence infectivity: LOS type, Opa protein expression
(.90% Opa negative), and piliation (P1, with .99% identical
pilE DNA sequences).
We used PCR analysis and Southern blotting to confirm that
the iga gene in FA1090iga 15b was insertionally inactivated and
that no duplication or rearrangement of the gene had oc-
curred. Iga1-Iga2 PCR products from the mutant were cleaved
by PacI (data not shown). A Southern blot of chromosomal
DNA from the mutant digested with ClaI and PacI and probed
with the Iga2 oligonucleotide showed that the probe-hybridiz-
ing fragment in FA1090iga 15b was shifted relative to that of
FA1090, revealing the extra PacI site within the IgaStop linker
in the mutant (Fig. 2).
The iga mutant lacked detectable IgA1 protease function.
Supernatant from a broth culture of FA1090iga 15b did not
cleave human IgA1, whereas undiluted and 1:10 dilutions of
culture supernatant from FA1090 A22 were able to do so (Fig.
3).
Experimental human infection with FA1090iga 15b. Five
volunteers were inoculated with 106 CFU of FA1090iga 15b;
four of the five became infected during the 5-day trial. Three
subjects developed a urethral exudate containing gram-nega-
tive diplococci within 2 days of inoculation. The fourth infected
FIG. 2. Southern blot analysis of chromosomal DNA from strains FA1090
A22 and FA1090iga 15b digested with ClaI, PacI, or ClaI-PacI and probed with
oligonucleotide Iga2, specific for the iga gene. The blot demonstrates the pres-
ence of the PacI site in the linker insertion used to inactivate the iga gene in the
mutant strain.
FIG. 3. IgA1 protease activity of strain FA1090iga 15b and colonies cultured
from human subjects infected with the mutant strain. Culture supernatants or
dilutions of culture supernatants were incubated with human IgA1 overnight,
subjected to SDS-PAGE (12% polyacrylamide), transferred to nitrocellulose,
and probed with antibody to human IgA. The first three lanes contain IgA1 that
was incubated with supernatant from wild-type strain FA1090 A22 cultures,
undiluted, diluted 1:10, and diluted 1:100. The fourth lane contains IgA1 that was
incubated with undiluted supernatant from a FA1090iga 15b culture. In the
remaining lanes, IgA1 was incubated with undiluted supernatant from cultures of
colonies isolated from FA1090iga 15b-infected subjects. A and B are two differ-
ent subjects; 1 and 2 indicate two different colonies cultured from each subject.
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subject developed a urethral discharge on the 4th day after
inoculation. Urethral swab specimens and urine specimens
from all four subjects were positive for gonococci. The fifth
subject showed no signs or symptoms of infection, and no
gonococci were cultured from urethral swab or urine speci-
mens. These results are similar to those we obtained in previ-
ous human challenge experiments with wild-type FA1090 vari-
ants A21 and A22, in which 89% of subjects inoculated with
106 CFU were infected (n 5 28). Subjects infected with either
of these Opa-negative, P1 variants of the wild-type strain de-
velop clinical signs of infection 1 to 4 days postinoculation
(references 4, 6, 9, and 12 and our unpublished observations).
The total number of CFU cultured from urine specimens ob-
tained when subjects infected with the iga mutant developed a
urethral discharge ranged from 3.2 3 104 to 1.3 3 105 total
CFU/urine specimen, which is within the range normally oc-
curring in FA1090-infected subjects (1 3 102 to 5 3 105 total
CFU/urine specimen) (references 4, 9, and 12 and our unpub-
lished observations). Similarly, leukocyte counts for subjects
infected with the mutant strain, which ranged from 5 to 38
leukocytes per mm3 of urine sediment, were within the range
for FA1090-infected subjects (our unpublished observations),
although the values were highly variable in both cases.
Genotypic and phenotypic characterization of gonococci iso-
lated from infected subjects. Using PCR analysis and IgA1
protease activity assays, we confirmed that the subjects who
became infected when inoculated with FA1090iga 15b were
indeed infected with bacteria that had an insertionally inacti-
vated iga gene and that lacked IgA1 protease activity. Primers
Iga1 and Iga2 were used to amplify a portion of the iga gene
from 24 individual colonies cultured from each of two of the
infected volunteers. In all cases, the resulting PCR products
were digested with PacI into two smaller fragments, showing
that the iga genes of the reisolates contained the PacI site that
is present in the IgaStop insertion (data not shown). To con-
firm that the presence of the IgaStop insertion was still asso-
ciated with lack of IgA1 protease activity, we assayed super-
natants from cultures grown from two IgaStop-containing
colonies isolated from each of two infected subjects; all were
unable to cleave human IgA1 (Fig. 3).
DISCUSSION
The well-documented association of IgA1 protease produc-
tion with pathogens that colonize mucosal surfaces has sug-
gested that this proteinase may contribute to the virulence of
such bacteria as N. gonorrhoeae, N. meningitidis, and Hae-
mophilus influenzae. Because the role played by IgA in host
mucosal defenses is not fully understood, it is difficult to pre-
dict how IgA1 cleavage would benefit an IgA1 protease-pro-
ducing organism. However, recent findings suggest that IgA1
protease and other iga gene products may influence the intra-
cellular fate of gonococci (1, 10, 20, 29). Using the human
challenge model, we assessed the role played by IgA1 protease
in the early stages of gonococcal infection. The Iga2 mutant of
N. gonorrhoeae FA1090 caused gonococcal urethritis in male
volunteers. In all respects, including the proportion of inocu-
lated volunteers infected, the signs and symptoms of infection,
the period of incubation between inoculation and infection,
and the numbers of CFU cultured from urine specimens, the
outcome of infection with FA1090iga 15b was indistinguishable
from the results we previously described for infection of sub-
jects with wild-type strain FA1090 variants A21 or A22 (refer-
ences 4, 6, 9, and 12 and our unpublished observations). These
results indicate that N. gonorrhoeae does not require produc-
tion of IgA1 protease to successfully colonize the male urethra
and cause urethritis. Because the sites of infection and types of
infection caused by different IgA1 protease-producing patho-
gens vary considerably, it is not appropriate to extrapolate
from this result with the gonococcus and attempt to draw
conclusions about the contribution that IgA1 protease makes
to the virulence of organisms other than gonococci.
Practical limitations preclude the study of large numbers of
subjects in this model of experimental gonococcal infection.
While we can reach broad conclusions about the ability of a
particular mutant to cause infection and can to some extent
characterize the severity of that infection, we cannot detect
slight differences in infectivity that may exist between mutant
and wild-type strains. The fact that the gonococcal Iga2 mu-
tant can cause urethritis in this model of infection does not
mean that the mutant is completely unimpaired in its ability to
initiate an infection. However, it is possible to render a gono-
coccal strain noninfectious in the human challenge model by
mutational inactivation of a single gene encoding a critical
virulence factor, as Cornelissen et al. (6) recently demon-
strated with a transferrin receptor mutant. Additionally, we
know that the experimental-infection model is sufficiently sen-
sitive to detect an attenuated phenotype with an intermediate
level of infection in which inoculated volunteers have positive
urine cultures but do not develop the normal clinical symptoms
of gonococcal infection (9). Any impairment of the infectivity
of the iga mutant, if such impairment exists, must be relatively
subtle.
For ethical reasons, we believe that treatment of human
subjects in these experimental trials must be initiated at the
onset of signs or symptoms of infection. Our assessment of the
events that occur in volunteers is limited to the early stages of
the infection process, including colonization and the subse-
quent inflammatory response, and excludes later times, when
an acquired immune response would come into play. It is
possible that Iga2 bacteria would not exhibit decreased viru-
lence until after the host initiated a specific antibody response
to infection. Perhaps IgA1 protease function does not contrib-
ute to uncomplicated infection but rather aids in establishing
invasive complications such as pelvic inflammatory disease.
Alternatively, IgA1 protease may play little or no role in a
naive host but may contribute to reinfection of a previously
exposed host by cleaving antibodies raised during an earlier
infection.
Given the potential for serious complications of gonococcal
infection in women, only male subjects can be studied by ex-
perimental infection. We can draw no conclusions from our
data about the role that IgA1 protease may play in female
gonococcal infection. The tissues of the female reproductive
system differ significantly from those of the male urogenital
tract, and within the female reproductive tract itself there are
several different anatomical sites at which the level and types of
Ig present can vary. To further complicate matters, both IgA
and IgG levels in the fallopian tubes, uterus, and cervix fluc-
tuate over the course of the menstrual cycle (15, 38). Clearly,
IgA1 protease may play a role in pathogenesis in females that
differs significantly from its role in males. However, in a recent
study, Hedges et al. (11) found no evidence for IgA1 protease
activity in cervical mucus or vaginal wash samples from women
with uncomplicated gonorrhea. As these authors pointed out,
their results do not exclude the possibility that IgA1 protease is
a more potent virulence factor in female infection when gono-
cocci are located in the subepithelium rather than in the lumen
or on the mucosal surface.
For several reasons, IgA1 protease has been viewed as an
appealing vaccine candidate for both N. gonorrhoeae and N.
meningitidis. It is produced by virtually all strains of gonococci
3012 JOHANNSEN ET AL. INFECT. IMMUN.
and meningococci, and neutralizing antibodies recognize
epitopes shared by the proteases of both species (21, 22). In a
recent study of vaccinated Gambian children, Thiesen et al.
(37) found that N. meningitidis IgA1 protease was highly im-
munogenic and that anti-IgA1 protease antibodies in serum
persisted or increased over a 5-year period. In the event that
mucosal responses to IgA1 protease are also strong and sus-
tained, IgA1 protease may prove to be a useful vaccine com-
ponent for some types of infection or reinfection. However,
our results suggest that targeting IgA1 protease alone would
not be sufficient to protect males from uncomplicated infection
with N. gonorrhoeae, since urethral infection occurred in the
absence of IgA1 protease activity.
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